Règles d'arrêt précoce dans les essais cliniques basées sur une surveillance séquentielle des événements indésirables graves

A. Kramar; C. Bascoul-Mollevi; S. Gourgou-Bourgade

Revue de Statistique Appliquée (2005)

  • Volume: 53, Issue: 4, page 49-59
  • ISSN: 0035-175X

How to cite

top

Kramar, A., Bascoul-Mollevi, C., and Gourgou-Bourgade, S.. "Règles d'arrêt précoce dans les essais cliniques basées sur une surveillance séquentielle des événements indésirables graves." Revue de Statistique Appliquée 53.4 (2005): 49-59. <http://eudml.org/doc/106572>.

@article{Kramar2005,
author = {Kramar, A., Bascoul-Mollevi, C., Gourgou-Bourgade, S.},
journal = {Revue de Statistique Appliquée},
language = {fre},
number = {4},
pages = {49-59},
publisher = {Société française de statistique},
title = {Règles d'arrêt précoce dans les essais cliniques basées sur une surveillance séquentielle des événements indésirables graves},
url = {http://eudml.org/doc/106572},
volume = {53},
year = {2005},
}

TY - JOUR
AU - Kramar, A.
AU - Bascoul-Mollevi, C.
AU - Gourgou-Bourgade, S.
TI - Règles d'arrêt précoce dans les essais cliniques basées sur une surveillance séquentielle des événements indésirables graves
JO - Revue de Statistique Appliquée
PY - 2005
PB - Société française de statistique
VL - 53
IS - 4
SP - 49
EP - 59
LA - fre
UR - http://eudml.org/doc/106572
ER -

References

top
  1. [1] ARMITAGE P., MCPHERSON C.K., ROWE B.C. ( 1969), Repeated signifiance test on accumulating data, Journal of the Royal Statistical Society, Series A,132 :232-244. MR250405
  2. [2] BRYANT R., DAY R. ( 1995), Incorporating toxicity considerations into the design of two-stage phase II trials, Biometrics, 51 :656-664. Zbl0871.62090
  3. [3] UDRAVIGILANCE-CLINICAL TRIALS MODULE (JUILLET 2002), Detailed guidance on the European data base of suspected unexpected serious adverse reactions, draft 2.8. 
  4. [4] GOLDMAN A.I., HANNAN P.J. ( 2001), Optimal continuous sequential boundaries for monitoring toxicity in clinical trials : a restricted search algorithm, Statistics in Medicine, 20 :1575-1589. 
  5. [5] HWANG I.K., SHIH W.J., DECANI J.S. ( 1990), Group sequential designs using a family of type I error probability spending functions, Statistics in Medicine, 9:1439-1445. 
  6. [6] KRAMAR A., POTVIN D., HILL C. ( 1996), Plans expérimentaux pour l'inclusion de patients dans les essais de phase II, Revue d'Epidémiologie et Santé Publique, 44 :364-371. 
  7. [7] LEE Y.J., WESLEY R.A. ( 1981), Statistical contributions to phase II trials in cancer : interpretation, analysis and design, Seminars in Oncology, 8 :403-416. 
  8. [8] O'BRIEN P.C., FLEMING T.R. ( 1979), A multiple testing procedure for clinical trials, Biometrics, 35 :549-556. 
  9. [9] O'OQUIGLEY J., SHEN L.Z. ( 1996), Continual reassessment method : a likelihood approach, Biométrics, 52 :673-684. Zbl0925.62454
  10. [10] POCOCK S.J. ( 1977), Group sequential methods in the design and analysis of clinical trials, Biometrika, 64 :191-199. 
  11. [11] ROSTI G., PICO J.-L., WANDT H., KOZA V., SALVIONI R., THEODORE C., LELLI G., SEIGERT W., HORWICH A., MARANGOLO M., SCHMOLL H.J., LINKESCH W., PIZZOCARO G., BOUZY J., KRAMAR A., DROZ J.-P. ( 2002), High dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumour; first results of a prospective randomised trial of the European Group for Blood and Marrow Transplantation (EBMT) : IT94 Proeeeding of ASCO, 132 :A716. 
  12. [12] SCHARFSTEIN D.O., TSIATIS A.A., ROBINS J.-M. ( 1997), Semiparametric efficiency and its implication on the design and analysis of group sequential studies, Journal of the American Statistical Association, 92 :1342-1350. Zbl0913.62075

NotesEmbed ?

top

You must be logged in to post comments.

To embed these notes on your page include the following JavaScript code on your page where you want the notes to appear.

Only the controls for the widget will be shown in your chosen language. Notes will be shown in their authored language.

Tells the widget how many notes to show per page. You can cycle through additional notes using the next and previous controls.

    
                

                
Note: Best practice suggests putting the JavaScript code just before the closing </body> tag.